These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32345355)

  • 1. Enhanced accumulation of N-terminally truncated Aβ with and without pyroglutamate-11 modification in parvalbumin-expressing GABAergic neurons in idiopathic and dup15q11.2-q13 autism.
    Frackowiak J; Mazur-Kolecka B; Mehta P; Wegiel J
    Acta Neuropathol Commun; 2020 Apr; 8(1):58. PubMed ID: 32345355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The link between intraneuronal N-truncated amyloid-β peptide and oxidatively modified lipids in idiopathic autism and dup(15q11.2-q13)/autism.
    Frackowiak J; Mazur-Kolecka B; Schanen NC; Brown WT; Wegiel J
    Acta Neuropathol Commun; 2013 Sep; 1():61. PubMed ID: 24252310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abnormal intracellular accumulation and extracellular Aβ deposition in idiopathic and Dup15q11.2-q13 autism spectrum disorders.
    Wegiel J; Frackowiak J; Mazur-Kolecka B; Schanen NC; Cook EH; Sigman M; Brown WT; Kuchna I; Wegiel J; Nowicki K; Imaki H; Ma SY; Chauhan A; Chauhan V; Miller DL; Mehta PD; Flory M; Cohen IL; London E; Reisberg B; de Leon MJ; Wisniewski T
    PLoS One; 2012; 7(5):e35414. PubMed ID: 22567102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction in parvalbumin expression not loss of the parvalbumin-expressing GABA interneuron subpopulation in genetic parvalbumin and shank mouse models of autism.
    Filice F; Vörckel KJ; Sungur AÖ; Wöhr M; Schwaller B
    Mol Brain; 2016 Jan; 9():10. PubMed ID: 26819149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of reduced expression of fragile X mental retardation protein in neurons and increased expression in astrocytes in idiopathic and syndromic autism (duplications 15q11.2-q13).
    Wegiel J; Brown WT; La Fauci G; Adayev T; Kascsak R; Kascsak R; Flory M; Kaczmarski W; Kuchna I; Nowicki K; Martinez-Cerdeno V; Wisniewski T; Wegiel J
    Autism Res; 2018 Oct; 11(10):1316-1331. PubMed ID: 30107092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships among parvalbumin-immunoreactive neuron density, phase-locked gamma oscillations, and autistic/schizophrenic symptoms in PDGFR-β knock-out and control mice.
    Nakamura T; Matsumoto J; Takamura Y; Ishii Y; Sasahara M; Ono T; Nishijo H
    PLoS One; 2015; 10(3):e0119258. PubMed ID: 25803852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraneuronal accumulation of amyloid-β peptides as the pathomechanism linking autism and its co-morbidities: epilepsy and self-injurious behavior - the hypothesis.
    Frackowiak J; Mazur-Kolecka B
    Front Mol Neurosci; 2023; 16():1160967. PubMed ID: 37305553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Number of Chandelier and Basket Cells Are Differentially Decreased in Prefrontal Cortex in Autism.
    Ariza J; Rogers H; Hashemi E; Noctor SC; Martínez-Cerdeño V
    Cereb Cortex; 2018 Feb; 28(2):411-420. PubMed ID: 28122807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of GABAergic neurons in the hippocampus and cerebral cortex of Engrailed-2 null mutant mice: implications for autism spectrum disorders.
    Sgadò P; Genovesi S; Kalinovsky A; Zunino G; Macchi F; Allegra M; Murenu E; Provenzano G; Tripathi PP; Casarosa S; Joyner AL; Bozzi Y
    Exp Neurol; 2013 Sep; 247():496-505. PubMed ID: 23360806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Number of Parvalbumin-Expressing Interneurons Is Decreased in the Prefrontal Cortex in Autism.
    Hashemi E; Ariza J; Rogers H; Noctor SC; Martínez-Cerdeño V
    Cereb Cortex; 2017 Mar; 27(3):1931-1943. PubMed ID: 26922658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences between the pattern of developmental abnormalities in autism associated with duplications 15q11.2-q13 and idiopathic autism.
    Wegiel J; Schanen NC; Cook EH; Sigman M; Brown WT; Kuchna I; Nowicki K; Wegiel J; Imaki H; Ma SY; Marchi E; Wierzba-Bobrowicz T; Chauhan A; Chauhan V; Cohen IL; London E; Flory M; Lach B; Wisniewski T
    J Neuropathol Exp Neurol; 2012 May; 71(5):382-97. PubMed ID: 22487857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyroglutamate-Aβ: role in the natural history of Alzheimer's disease.
    Gunn AP; Masters CL; Cherny RA
    Int J Biochem Cell Biol; 2010 Dec; 42(12):1915-8. PubMed ID: 20833262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical Evidence from APP-Transgenic Mice for Glutaminyl Cyclase as Drug Target to Diminish pE-Abeta Formation.
    Hartlage-Rübsamen M; Bluhm A; Piechotta A; Linnert M; Rahfeld JU; Demuth HU; Lues I; Kuhn PH; Lichtenthaler SF; Roßner S; Höfling C
    Molecules; 2018 Apr; 23(4):. PubMed ID: 29673150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural alterations in fast-spiking GABAergic interneurons in a model of posttraumatic neocortical epileptogenesis.
    Gu F; Parada I; Shen F; Li J; Bacci A; Graber K; Taghavi RM; Scalise K; Schwartzkroin P; Wenzel J; Prince DA
    Neurobiol Dis; 2017 Dec; 108():100-114. PubMed ID: 28823934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyroglutamate-modified amyloid-β protein demonstrates similar properties in an Alzheimer's disease familial mutant knock-in mouse and Alzheimer's disease brain.
    Wu G; Miller RA; Connolly B; Marcus J; Renger J; Savage MJ
    Neurodegener Dis; 2014; 14(2):53-66. PubMed ID: 24158021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased parvalbumin and somatostatin neurons in medial prefrontal cortex in BRINP1-KO mice.
    Kobayashi M; Hayashi Y; Fujimoto Y; Matsuoka I
    Neurosci Lett; 2018 Sep; 683():82-88. PubMed ID: 29960053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyroglutamate-modified amyloid beta-peptides--AbetaN3(pE)--strongly affect cultured neuron and astrocyte survival.
    Russo C; Violani E; Salis S; Venezia V; Dolcini V; Damonte G; Benatti U; D'Arrigo C; Patrone E; Carlo P; Schettini G
    J Neurochem; 2002 Sep; 82(6):1480-9. PubMed ID: 12354296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Purification and Characterization of Recombinant N-Terminally Pyroglutamate-Modified Amyloid-β Variants and Structural Analysis by Solution NMR Spectroscopy.
    Dammers C; Gremer L; Neudecker P; Demuth HU; Schwarten M; Willbold D
    PLoS One; 2015; 10(10):e0139710. PubMed ID: 26436664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Astrocytes and microglia but not neurons preferentially generate N-terminally truncated Aβ peptides.
    Oberstein TJ; Spitzer P; Klafki HW; Linning P; Neff F; Knölker HJ; Lewczuk P; Wiltfang J; Kornhuber J; Maler JM
    Neurobiol Dis; 2015 Jan; 73():24-35. PubMed ID: 25204716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyroglutamate and Isoaspartate modified Amyloid-Beta in ageing and Alzheimer's disease.
    Moro ML; Phillips AS; Gaimster K; Paul C; Mudher A; Nicoll JAR; Boche D
    Acta Neuropathol Commun; 2018 Jan; 6(1):3. PubMed ID: 29298722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.